Abstract
Here, we report a case of metastatic Epstein-Barr virus (EBV)-related primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) in a young, nonsmoking female who responded well to treatment with two types of immune checkpoint inhibitors (ICIs). This is the first case report of a favorable outcome to ICIs in the late-line treatment of advanced PPLELC patients with programmed cell death-ligand 1 (PD-L1) expression.